Clinical Trial Update: Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing Nexium 40 mg once daily to Prevacid 30 mg twice daily for control of severe gastroesophageal reflux disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Nexium (esomeprazole)
• PREVACID (LANSOPRAZOLE)

Snippet

Sponsor: Digestive & Liver Disease Specialists | Conditions: GERD | Phase 4 | Status: COMPLETED